OpGen’s Acuitas® AMR Gene Panel Shows Potential for Reducing Total Time to Targeted Therapy Collaborator data demonstrating OpGen’s rapid prediction of antibiotic resistance and detection of uropathogens presented at ASM Microbe 2019 GAITHERSBURG, Md., June 27, 2019 (GLOBE NEWSWIRE) --...

OpGen Announces New Data Demonstrating Clinical Utility for Antibiotic Resistant Urinary Tract Infection Patient Management and for Rapid Carbapenem-Resistant Bacteria Outbreak Detection GAITHERSBURG, Md., June 13, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that data from its Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software will be presented at ASM...

OpGen Completes Initial FDA 510(k) Submission for its Acuitas® AMR Gene Panel Test to Identify Presence of Antibiotic Resistance GAITHERSBURG, Md., May 14, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that it has filed its 510(k) submission with the U.S. Food and Drug Administration (FDA) for clearance...

OpGen and Merck’s ILÚM Health Solutions to Host Event at VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship GAITHERSBURG, Md., March 25, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today it will host an event with ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary of Merck’s...

OpGen, Inc. to Host Anti-Infectives Roundtable at the World Anti-Microbial Resistance Congress GAITHERSBURG, Md., Sept. 08, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will participate in the World Anti-Microbial Resistance Congress being held September 8-9 in...